Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility

Area of Science:

• Biomedical Engineering
• Pharmacology
• Reproductive Biology

Background:

• Physiological changes during the female menstrual cycle can alter drug delivery.
• Nanoparticle biodistribution is influenced by hormonal fluctuations.
• Understanding these changes is crucial for effective nanomedicine development.

Purpose of the Study:

• To investigate the effect of the menstrual cycle on nanoparticle biodistribution in female reproductive organs.
• To evaluate the impact of ovulation timing on the efficacy and toxicity of nanomedicines for cancer treatment.
• To determine if nanoparticle administration during ovulation affects ovarian toxicity and fertility.

Main Methods:

• Intravenous administration of nanoparticles (100 nm or smaller) in murine models.
• Comparison of nanoparticle accumulation in ovaries and uterus during ovulatory and non-ovulatory stages.
• Assessment of therapeutic efficacy and toxicity of drug-loaded nanoparticles in ovarian and breast cancer models.
• Evaluation of ovarian toxicity and fertility after nanoparticle administration during ovulation.

Main Results:

• A 2-fold increase in nanoparticle accumulation in murine ovaries and uterus was observed during ovulation compared to the non-ovulatory stage.
• Nanomedicine efficacy for ovarian cancer improved when administered during ovulation due to increased ovarian drug accumulation.
• Conversely, breast cancer treatment efficacy decreased during ovulation due to altered nanoparticle biodistribution.
• Chemotherapeutic nanoparticles administered during ovulation led to increased ovarian toxicity and reduced fertility.

Conclusions:

• The female menstrual cycle significantly influences nanoparticle biodistribution within the reproductive system.
• Ovulation timing affects nanomedicine efficacy and toxicity, with potential benefits for ovarian cancer and risks for other cancers.
• Consideration of the menstrual cycle is essential for optimizing nanomedicine design and administration in females to maximize therapeutic benefits and minimize adverse effects.